- Home
- KRO vs ZURA Comparison
KRO vs ZURA Comparison
Compare KRO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRO | ZURA |
|---|---|---|
| Founded | 1916 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.9M | 595.9M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | KRO | ZURA |
|---|---|---|
| Price | $5.43 | $5.48 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $6.00 | ★ $11.78 |
| AVG Volume (30 Days) | 307.8K | ★ 520.3K |
| Earning Date | 03-09-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,859,400,000.00 | N/A |
| Revenue This Year | $3.47 | N/A |
| Revenue Next Year | $11.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.08 | $0.99 |
| 52 Week High | $7.94 | $7.25 |
Technical Indicators
Market Signals| Indicator | KRO | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 36.66 |
| Support Level | $5.14 | $3.33 |
| Resistance Level | $5.85 | $5.75 |
| Average True Range (ATR) | 0.32 | 0.53 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 51.14 | 3.73 |
Price Performance
Historical ComparisonAbout KRO Kronos Worldwide Inc
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.